Compare Heron Therapeutics Inc (HRTX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.79. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VWO | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $61.24 |
52-Week Low | $0.39 | $49.54 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's low expense ratio of 0.06% and 2.4% dividend yield (The Motley Fool, 2026-06-29) appeal to cost-conscious investors. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exposure to developing economies without heavy China reliance.
Outlook: VWO offers diversified emerging market access at low cost, but faces risks from geopolitical tensions and China's economic volatility. Investor sentiment is mixed, with technicals suggesting caution despite fundamental strengths in expense efficiency and yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
